Latest Regulatory Compliance News

MIXI Australia has secured majority voting power in PointsBet, pushing the takeover offer deadline to mid-September and setting the stage for full control.

Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.

Prescient Therapeutics has completed a $3 million share placement, bolstering its clinical development programs for innovative cancer treatments including PTX-100 and novel cell therapies.

Alligator Energy has lodged a Prospectus for Placement Options following its June 2025 capital raise, setting the stage for potential shareholder dilution and future funding opportunities.

Finexia Financial Group's shares have been suspended from trading pending a significant announcement related to media speculation and a potential material acquisition.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

The Star Entertainment Group reported a statutory net loss of $471.5 million for FY25, impacted by regulatory reforms and remediation costs, while securing a $300 million strategic investment to bolster liquidity.

Broken Hill Mines Limited reported a $2.42 million loss for FY2025 amid a transformative acquisition of Broken Hill Mines Holdings Pty Ltd and a $20 million capital raise, marking its relisting on the ASX under the code BHM.

Savannah Goldfields Limited is poised to restart gold production in 2025 at its Georgetown and Agate Creek sites, backed by solid ore reserves and ambitious exploration plans to extend mine life.

Dusk Group Limited reported solid financial growth for FY25, with revenue up 7.8% and net profit rising 5.5%, underpinned by strong online sales and strategic store expansions.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.